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present study, we report on the clinical and economical outcomes associated with 
omalizumab use in a cohort (n  23) of Italian adult asthmatics treated for a mean of 
10 months (range: 2–22). The pharmacoeconomic value of the treatment is assessed 
with the cost/utility ratio evaluation. RESULTS: Omalizumab signiﬁcantly improved   
asthma control and these patients’ health-related quality of life, with respect to the 
year preceding its inclusion in their therapeutic strategy. Despite reducing the costs of 
symptomatic drugs and hospital care for this patient population, the net economic 
effect of omalizumab introduction is an estimated increase of about a350 in overall 
monthly costs. However, when related to the increase in health beneﬁts, this cost 
increase results in an incremental cost/utility ratio of about a26,000/quality-adjusted 
life years gained, a favourable value according to the willingness to pay for health ben-
eﬁts in industrialised countries. CONCLUSIONS: Omalizumab therapy signiﬁcantly   
improved clinical outcomes in difﬁcult-to-treat asthmatic patients. Costs also increased, 
but this increase appears to be justiﬁed by the important clinical beneﬁts achieved.
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OBJECTIVES: It is hypothesised that the presence of ocular manifestations (Oc         Ns) 
in addition to nasal symptoms (Ns) places an additional burden on Allergic Rhinitis 
patients. This study investigated the impact on the Quality of Life (QoL) and Burden 
of Illness (BoI) among AR patients in France, Germany, Italy and Spain. METHODS: 
The data were drawn from a cross-sectional study of consulting patients undertaken 
in May/June 2008 (Adelphi). Data were collected by doctors who included records 
relating to the next consecutive 4–5 patients consulting for AR. Patients were invited 
to ﬁll out self-completion questionnaires: QoL and work productivity measures such 
as Mini-RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire), PSQI (Pittsburgh 
Sleep Quality Index) and WPAI (Work Productivity and Activity Impairment question-
naire). Propensity scoring (PS) methods were used to match the two comparison 
groups (OcNs patients vs Ns only) RESULTS: The total sample size was 750 and       
70% of these patients (526) presented with both symptoms (OcNs). The results were 
consistent in all domains of the QoL tools with OcNs patients displaying poorer 
QoL. Clinically differences were found in the overall quality of life (RQLQ) score 
(2.54 vs. 1.96, p  0.01). Regarding sleep quality (measured by the PSQI), the global 
score showed a statistically difference (5.41 vs. 4.57, p  0.05), with the OcNs group 
falling in the “poor sleepers” category (score above 5). Regular activities (36% vs. 
29%, WPAI : AS percent impairment, P  0.05) and impact on work (0.8 vs. 0.3 days, 
time off work due to AR in the last 3 months, p  0.05) also showed a higher burden 
in OcNs patients. CONCLUSIONS: AR patients with both ocular and nasal symp-       
toms have signiﬁcantly poorer QoL and quality of sleep and take more time off 
work/usual activities than those with nasal symptoms only. These patients would 
beneﬁt from therapies that are proven to speciﬁcally address ocular symptoms in 
addition to nasal symptoms.
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OBJECTIVES: It is hypothesised that the presence of ocular symptoms (Oc         Ns) in 
addition to nasal symptoms (Ns) results in additional resource utilization. This study 
investigated the impact on burden of illness (BoI) among AR patients in France, 
Germany, Italy and Spain. METHODS: The data were drawn from a cross-sectional       
study of consulting patients undertaken in May/June 2008 (Adelphi). Data were col-
lected by doctors who included records relating to the next consecutive 4–5 patients 
consulting for AR. Patients were invited to ﬁll the WPAI (Work Productivity and 
Activity Impairment) questionnaire. Propensity scoring (PS) methods were used to 
match the two comparison groups (OcNs patients vs Ns only). RESULTS: A total 
of 1009 patients meeting the inclusion criteria of which 69% (700) presented with            
both symptoms (OcNs). The OcNs patients were prescribed 15% more AR medica-
tions (e.g. inhaled nasal corticosteroids, NSAs; 1.6 vs. 1.4, p  0.05) and required 
23% more consultations with health care services concerning their AR condition (4.9 
vs. 4.0, p  0.05). Of the 1009, 750 ﬁlled in the self-completion questionnaire (includ-
ing 526 OcNs patients). All work related AR WPAI domains were statistically dif-
ferent with OcNs patients recording greater impact including proportion of work 
time (hours) missed due to AR in the last 7 days (3.3% vs. 0.7%, p  0.05), impair-
ment while working (hours worked in the last 7 days, 32.6% vs. 21.8%, p  0.05) In 
addition, OcNs patients recorded more actual days off work due to AR over the 
preceding 3 months compared with patients with nasal symptoms only (0.8 vs. 0.3 
days p  0.05). CONCLUSIONS: AR patients with both ocular and nasal symptoms        
place a signiﬁcant additional burden on resource utilisation and experience greater 
lost productivity than those with nasal symptoms only. Therapies that are proven to 
speciﬁcally address ocular in addition to nasal symptoms would result in beneﬁts from 
both the direct and indirect costs associated with AR.
RESPIRATORY-RELATED DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: To compare prescription patterns and treatment adherence to inhaled 
corticosteroids (ICS) and leukotriene-receptor antagonists (LTRA) among asthmatic 
children. METHODS: Using the Quebec (Canada) administrative health databases, 
we identiﬁed a cohort of 27,355 asthmatic children aged 5 to 15 years in whom 
monotherapy with ICS or LTRA was initiated between January 1, 1998 and August 
31, 2005. Prescription patterns were examined by the proportion of days’ supply 
prescribed (PDSP: number of days with supply prescribed from all physicians a patient 
consulted over the number of days of follow-up). Adherence to therapy was estimated 
by the proportion of prescribed days covered (PPDC: number of days’ supply dis-
pensed over the number of days’ supply prescribed during the follow-up). The mean 
PDSP and PPDC were compared between ICS and LTRA patients using t-tests. All 
analyses were stratiﬁed by the presence or the absence of an asthma exacerbation in 
the year prior to treatment initiation with ICS or LTRA. RESULTS: Among patients 
who had an asthma exacerbation, 7427 initiated ICS and 67 initiated LTRA therapy. 
Corresponding ﬁgures were 19439 and 422 among patients who did not have an 
asthma exacerbation. The mean PPDC was similar between ICS and LTRA users in 
both strata (68.0 % vs 64.7% in the exacerbation stratum and 63.9 vs 62.7 in the no 
exacerbation stratum), but the PDSP was signiﬁcantly lower among ICS users (32.8% 
vs 55.9% (p-value 0.001) in the exacerbation stratum and 34.0% vs 51.9% (p-value 
0.001) in the no exacerbation stratum). CONCLUSIONS: Asthmatic children treated 
with ICS and LTRA had similar treatment adherence to the prescribed medications, 
but ICS appeared to be more frequently prescribed as an intermittent rather than a 
daily controller therapy, resulting in lower usage of ICS.
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INTRODUCTION: In a recent report, AFSSAPS (the French Health Products Safety 
Agency) discussed to what extent the dose selected constitutes an important success 
factor. OBJECTIVES: Assess the impact of quitting smoking in subjects receiving treat-
ment by nicotine patches, combined in some cases (and others not, depending on the 
practitioners’ approach) with nicotine pastilles to suck. METHODS: Each of the sub-
jects was included after they had expressed, during the spontaneous consultation, their 
desire to quit smoking. The cohort being pragmatic, no prescription advice was given, 
directly or indirectly, to the investigating doctors. The doctors were recruited by an 
independent service provider. Should the name of the products used not be cited? 
RESULTS: A total of 215 subjects were recruited by 67 general practitioners. Two            
analysis groups were organised, the ﬁrst group being treated with a transdermal device 
or skin patch (n  93) and the second with a transdermal device combined with pastilles 
(n  122). After 6 months, the rate of abstinence in the “Patch  Pastille” group was 
62.1% versus 39.7% in the “Patch only” group, the difference observed being signiﬁcant 
(p  0.008). CONCLUSIONS: This cohort, carried out in real conditions, highlights—in 
subjects wishing to quit smoking—the relevance of adjusting the dose with the help of 
pastilles. Therefore, it would appear that, for subjects quitting smoking, combining 
pastilles with a transdermal nicotine substitute is indispensable. The role of the health 
professional initiating the quitting programme is therefore of prime importance.
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OBJECTIVES: To develop and validate an algorithm to report utilities from the 
EXACT for use in cost-effectiveness studies in the UK. Current methods to derive 
utilities for exacerbations of COPD tend to be insensitive and unresponsive to change, 
including the widely used EQ-5D. There is a need to develop a measure that captures 
the full exacerbation experience with precision and responsiveness. The EXACT is a 
condition-speciﬁc PRO developed to measure the frequency, severity, and resolution 
of COPD exacerbations. METHODS: The EXACT items reduced using Rasch analy-
ses. Remaining items and levels grouped to form health states. States cognitively 
debriefed using patients to ensure combined wording and structure were appropriate. 
Members of the general public interviewed to value 11 health states each (including 
best/worst states) using the time trade-off (TTO) technique from full health/dead over 
10 years, with worse than dead values possible. Analyses include regression techniques 
to develop models that best predict utilities. Models assessed by number of inconsisten-
cies in the health state utilities, adjusted R2, and mean squared errors. Selected model 
validated using two separate datasets—one to test the predictive properties and one 
to test responsiveness and construct validity. RESULTS: Five items with 3 to 5 levels 
were selected to comprise the EXACT-U. Health states debriefed with 14 patients 
experiencing an exacerbation within the last 6 months. Total of 60 health states 
